menu search

JANX / Janux Therapeutics to Present at Upcoming March Investor Conferences

Janux Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in three upcoming investor conferences: Cowen's 42nd Annual Health Care Conference Forum: Panel titled “Novel IO” Location: Virtual Date: Monday Read More
Posted: Mar 1 2022, 08:01
Author Name: Business Wire
Views: 102038

JANX News  

All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy

By Zacks Investment Research
July 20, 2023

All You Need to Know About Janux Therapeutics, Inc. (JANX) Rating Upgrade to Buy

Janux Therapeutics, Inc. (JANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m more_horizontal

Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade

By Zacks Investment Research
July 20, 2023

Wall Street Analysts Believe Janux Therapeutics, Inc. (JANX) Could Rally 120.65%: Here's is How to Trade

The consensus price target hints at a 120.7% upside potential for Janux Therapeutics, Inc. (JANX). While empirical research shows that this sought-aft more_horizontal

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 9, 2023

Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Tops Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compare more_horizontal

Janux Therapeutics, Inc. (JANX) Surges 5.9%: Is This an Indication of Further Gains?

By Zacks Investment Research
February 14, 2023

Janux Therapeutics, Inc. (JANX) Surges 5.9%: Is This an Indication of Further Gains?

Janux Therapeutics, Inc. (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate re more_horizontal

Janux Therapeutics to Present at Upcoming March Investor Conferences

By Business Wire
March 1, 2022

Janux Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunoth more_horizontal

Janux Therapeutics to Present at Upcoming March Investor Conferences

By Business Wire
March 1, 2022

Janux Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunoth more_horizontal

Janux Therapeutics to Present at Upcoming March Investor Conferences

By Business Wire
March 1, 2022

Janux Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunoth more_horizontal


Search within

Pages Search Results: